Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): Results of the sCR2 international study

Annals of Oncology

Volumn 19, Issue 2, 2008, Pages 259-264

  Fizazi, K ^a   Oldenburg, J ^b   Dunant, A ^a   Chen, I ^c   Salvioni, R ^d   Hartmann, J T ^e   De Santis, M ^f   Daugaard, G ^g   Flechon, A ^h   De Giorgi, U ⁱ   Tjulandin, S ^j   Schmoll, H J ^k   Bouzy, J ^a   Fossa, S D ^b   Fromont, G ^l  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f LBI ACR ^*  (Austria)

^g Rigshospitalet   (Denmark)

^h CENTRE LÉON BÉRARD   (France)

ⁱ SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^j N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^k MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^l POITIERS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Chemotherapy; Germ cell tumor; Non seminoma; Residual masses; Surgery

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CHORIONIC GONADOTROPIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE; VINBLASTINE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW RESCUE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ASSESSMENT TOOL; DISEASE FREE SURVIVAL; DRUG MEGADOSE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SURGICAL COMPLETE RESPONSE 2; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; VALIDATION STUDY;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, GERM CELL AND EMBRYONAL; ORCHIECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TESTICULAR NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 38849124806     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm472     Document Type: Article

References (19)

1. Schmoll HJ, Souchon R, Krege S et al. European consensus on diagnosis and treatment at germ cell cancer: A report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2001; 15: 1377-1399.
2. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncoll 1997; 15: 594-603.
3. Fizazi K, Culine S, Kramar A et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 2004; 22: 3868-3876.
4. Mazumdar M, Bajorin DF, Bacik J et al. Predicting outcome to chemotherapy in patients with germ cell tumors: The value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol 2001; 19: 2534-2541.
5. Fizazi K, Tjulandin S, Salvioni R et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy - results from an international study group. J Clin Oncol 2001; 19: 2647-2657.
6. Oldenburg J, Alfsen GG, Lien HH et al. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol. 2003; 21: 3310-3317.
7. Andre F, Fizazi K, Cullne S et al. The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer 2000; 36; 1389-1394.
8. Fizazi K, Culine S, Droz JP et al. Primary mediastinal non-seminomatous germ cell tumors: Results of modern therapy including cisplatin-based chemotherapy. J Clin Oncol 1998; 16: 725-732.
9. El Mesbahl O, Terrier-Lacombe MJ, Rebischung C et al. Chemotherapy in patients with teratoma with malignant transformation. Eur Urol 2007; 51: 1306-1311.
10. Donadio A.C., Motzer RJ, Bajorin DF et al. Chemotherapy for teratoma with malignant transformation. J Clin Oncol 2003; 21: 4285-4291.
11. Hartmann JT, Candelaria M, Kuczyk MA et al. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer 1997; 33: 843-847.
12. Besse B, Flechon A. Caty C et al. No need for contralateral lung surgery in case of evidence of post-chemotherapy necrosis alone in residual lung masses in patients with disseminated non seminomatous germ cell tumors. Proc Am Soc Clin Oncol 2005; 23: 383 (Abstr 4524).
13. Fox, EP, Weathers TS, Williams, SD et al. Outcome analysis for patients with persistent non teratomatous germ-cell tumor in post chemotherapy retroperitoneal lymph node dissections. J Clin Oncol 1993; 11: 1294-1299.
14. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343-346.
15. Heidenreich A, Ohlmann C, Hegele A et al. Repeat retroperitoneal lymphadenectomy in advanced testicular cancer. Eur Urol 2005; 47: 64-71.
16. Rick O, Bokemeyer C, Weinknecht S et al. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. J Clin Oncol 2004; 22: 3713-3719.
17. Berney DM, Shamash J, Hendry WF et al. Prediction of relapse after lymph node dissection for germ cell tumours: Can salvage chemotherapy be avoided? Br Cancer 2001; 84: 340-343.
18. Mayer F, Honecker F, Looijenga LH et al. Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors. Ann Oncol 2003; 14: 825-832.
19. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-991.